Immune thrombocytopenia featured most prominently at the Meeting but new data was presented for several forms of the disease.
Heme Today
Heme Today covers the latest news and analyses in bleeding, clotting, red blood cell, and iron disorders for hematologists and oncologists focused on bleeding disorders.
Advertisement
Latest News
PGK1 antibody levels in patients with recovered immuno-related pancytopenia were negatively correlated with platelet levels.
Thrombosis history was not predictive of overall survival in patients with pulmonary hypertension risk and PV, a study found.
The oral agent exhibited promising hemoglobin response performance and safety in this stage of an ongoing phase 2/3 study.
The first-in-class agent operates by increasing both von Willebrand factor and factor VIII levels in patients.
Imetelstat is indicated for patients with lower-risk MDS who had an unsatisfactory response to or are ineligible to ESAs.
In findings arterial thrombosis carried worse overall survival than venous thrombosis in this patient population.
CTD402 will enter a single-arm, open-label, phase 1b/2 trial aimed to optimize dosing and accelerate clinical development.
Clinical trials are ongoing to evaluate this orally available, selective inhibitor of XPO1 as part of combination regimens.
The panel's discussion, moderated by Neil Love, MD, dove especially into the nuances of using avapritinib and ruxolitinib.
Thomas Martin, MD, presented data on CAR-T, bispecifics, and BCMAs in MM the National General Medical Oncology Summit.
Advertisement
Conference Coverage
Major highlights with a focus on MDS from the 66th American Society of Hematology Annual Meeting & Exposition
Heme Today reports from the EHA 2024 Hybrid Congress the latest findings in hematology research and management.
Our editors are covering data on transplantation and cellular therapies from the 2024 Tandem Meetings of ASTCT® and ...
Highlighting the latest news and experts in pediatric hematology and oncology from the 2024 ASPHO Conference in Seattle.
Expert Interviews on Hematology
Blood Cancer Awareness
A phase II trial calculated a 4-year event-free survival rate of 96% and overall survival rate of 100% from the combination.
Differences were identified between patient racial groups and by urban versus rural populations.
A magnetic resonance imaging study has compared tissue iron levels and biventricular function between the two conditions.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.